AVENTURA, Fla., July 14, 2011 /PRNewswire/ — Double Eagle
Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse
Science, Inc. (
www.fusescience.com), announced today that it has entered into
a research and development agreement with Platform Delivery
Technologies Inc. (PDT Inc.), a California-based pharmaceutical
consulting firm. Double Eagle Holdings is the parent company of
Fuse Science, Inc., the developer of new, patent-pending
technologies poised to redefine how consumers receive energy,
medicines, vitamins and minerals.
The team at PDT Inc. has been responsible for numerous product
formulations currently on the market, including line extensions for
Chloraseptic, private label electrolyte replacement formulas for
national drugstore chains, Zicam Cold formulas and several
prescription pharmaceuticals. The PDT Inc. team has more than 30
pending and issued patents in the pharmaceutical and sports
performance industries.
“PDT Inc. has provided exclusive formulations and proprietary
branding for many of the world’s top pharmaceutical companies.
Through this agreement, our ability to bridge into several major
product categories is a certainty,” said Brian Tuffin, Fuse Science
President and Chief Operating Officer. “Our strong working
relationship will accelerate our commercialization efforts.”
Under the terms of the agreement, PDT Inc. will oversee a team
of scientists facilitating the formulation and manufacturing of
several Fuse Science products that leverage the Company’s
industry-leading Fusome Technology. The team’s focus will be
ongoing product innovation while working to advance Fuse Science’s
technology, intellectual property and patents. Rob Davidson, the
team’s managing director, reported today that PDT Inc. has already
completed work on three new industry standards and proprietary
formulations as Fuse Science prepares to enter the sports nu
‘/>”/>
